FDA approves Novo Nordisk’s new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile

Novo Nordisk acknowledges receipt of Warning Letter and welcomes further dialogue with the US FDA

Novo Nordisk expands US patient access to FDA-approved semaglutide medicines through Hims & Hers in response to a shift in their US GLP-1 business model